BridgeBio Pharma, Inc. (BBIO) 旗下药物Bbp-418在其针对肢带型肌营养不良症2i/R9型(Lgmd2i/R9)的3期Fortify临床试验的中期分析中,取得了积极结果。数据显示,该候选疗法不仅表现出持续且一致的有效性,还展现出良好的安全性与耐受性特征。这一关键进展为该药物的后续开发及潜在监管申请提供了有力支持。
BridgeBio Pharma, Inc. (BBIO) 旗下药物Bbp-418在其针对肢带型肌营养不良症2i/R9型(Lgmd2i/R9)的3期Fortify临床试验的中期分析中,取得了积极结果。数据显示,该候选疗法不仅表现出持续且一致的有效性,还展现出良好的安全性与耐受性特征。这一关键进展为该药物的后续开发及潜在监管申请提供了有力支持。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.